Filing Flows

Filing Flows › Precision Biosciences (DTIL) › Who owns the stock

Who owns Precision Biosciences (DTIL) stock

94 funds reported Precision Biosciences (DTIL) shares in their latest 13F filings, worth $139M in all. The largest holder is abrdn ($17.5M). Last quarter 57 funds added to their stakes and 27 cut them.

Largest holders of DTIL (13F)Largest holders of DTIL (13F)abrdn$17.5MBleichroeder LP$15.9MOctagon Capital Advisors LP$10.6MBoothbay Fund Management, LLC$10.6MBlackRock$9.2MVanguard Capital Management LLC$8.8MLynx1 Capital Management LP$7.5MDriehaus Capital Management LLC$7.4MEmpery Asset Management, LP$6.1MAffinity Asset Advisors, LLC$5.1M

Largest holders (13F)

FundSharesValueChangeQuarter
abrdn2,230,178$17.5Munchanged2026-06-30
Bleichroeder LP2,018,190$15.9Mincrease2026-06-30
Octagon Capital Advisors LP1,350,000$10.6Mdecrease2026-06-30
Boothbay Fund Management, LLC1,346,004$10.6Mincrease2026-06-30
BlackRock1,172,873$9.2Mincrease2026-06-30
Vanguard Capital Management LLC1,116,241$8.8Mincrease2026-06-30
Lynx1 Capital Management LP950,466$7.5Mdecrease2026-06-30
Driehaus Capital Management LLC946,707$7.4Mdecrease2026-06-30
Empery Asset Management, LP776,093$6.1Mdecrease2026-06-30
Affinity Asset Advisors, LLC646,576$5.1Mincrease2026-06-30
Geode Capital Management, LLC620,981$4.9Mincrease2026-06-30
Vanguard Group906,782$3.8Mincrease2025-12-31
State Street427,325$3.4Mincrease2026-06-30
Acadian Asset Management LLC305,759$2.4Mincrease2026-06-30
ArrowMark Colorado Holdings LLC274,140$2.2Mincrease2026-06-30

Precision Biosciences' latest quarter

Precision Biosciences, Q3 FY26: revenue $10.8M (374× year over year), operating margin -83.7%, net loss $18.4M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most DTIL stock?

By the latest 13F filings: abrdn ($17.5M); Bleichroeder LP ($15.9M); Octagon Capital Advisors LP ($10.6M); Boothbay Fund Management, LLC ($10.6M); BlackRock ($9.2M).

What is the short interest in DTIL?

2,356,838 shares were sold short at the 2026-10-15 settlement, -6.25% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.